Description
The cisplatin-resistant variant of the mouse mammary tumour cell line EMT6/P was derived by continuous in vitro exposure to increasing concentrations of cisplatin over a period of 6 weeks. EMT6/CPR was shown to express 2.5-fold resistance to cisplatin as compared with the sensitive parent line. Development of drug resistance was accompanied by a 1.7-fold increase in cellular glutathione (GSH). Growth for 4 weeks in the absence of cisplatin was reported to lead to loss of resistance phenotype and elevated GSH levels in the resistant cell line EMT6/CPR.
Adherent Suspension
Adherent
Suggested Medium
MEM(EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 0.25µg/ml, cisplatin + 10% Foetal Bovine Serum (FBS).
Quality Control
EMT6/CPR Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Morphology
Epithelial-like
Shippment
EMT6/CPR Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
EMT6/CPR Cell Line is for research use only
